Navamedic (NAVA)

Quadruple · desember 27, 2021, 11:14am

60% kursoppgang hittil i år og godt skodd for videre oppgang i 2022.
Lykke til i det nye året!

Quadruple · januar 26, 2022, 9:07am

Norne tar opp analysedekning med kursmål 50:

“A pharma gem that begins to sparkle”

“We initiate coverage of Navamedic, a pharmaceutical company that supplies hospitals and pharmacies with medicine and medical nutrition products. Navamedic offering notably in the obesity and consumer health sectors leads strong revenue growth. Over the past few years, the company has made significant changes in its management, company structure and strategy. Navamedic is well on track to reach its mid-term ambitious goals of becoming a NOK 500m revenue company with 15% EBITDA margin. We also see solid upside potential and issue a Buy recommendation with a DCF-based TP of NOK 50/share.”

TekBot · februar 14, 2022, 1:31pm

Navamedic ASA: Invitation to 2021 Fourth quarter presentation

TekBot · februar 16, 2022, 3:41pm

Navamedic ASA launches SmectaGO[®] - an innovative on-the-go product for treatment of diarrhea

Oslo, 16 February 2022 - Navamedic ASA (OSE: NAVA) today announces the launch of
SmectaGO[®] for sale through pharmacies in Norway, Sweden, Finland and Denmark
this spring. SmectaGO[®] is a unique product developed to treat acute and
…

Vis børsmeldingen

chronic diarrhea in adults and children above 8 years. The launch is part of a
long-term agreement with the well known French pharmaceutical corporation Ipsen
Consumer HealthCare wherein Navamedic has been appointed the exclusive partner
in the Nordics.

“Diarrhea and other gastro conditions are very common, but in the Nordics, we
know from research that only 20 percent of those suffering from such conditions
seek treatment. We can improve many people’s lives through driving awareness and
knowledge of treatment options. With our local insights and market access,
Navamedic intends to drive the development of this category in the Nordics, and
with SmectaGO®, we can offer a unique product to Nordic consumers. SmectaGO® is
already well established on the European continent and has been a favourite for
a long time for the treatment of diarrhea. We are honored that Ipsen Consumer
HealthCare selected Navamedic as their Nordic partner for this product range,”
says Kathrine Gamborg Andreassen, CEO of Navamedic ASA.

“This cooperation embodies the purpose of our Consumer HealthCare Division,
which is to bring people across the world care and comfort in their daily lives
with healthcare solutions they can trust. Indeed, it is a great opportunity to
touch more patients with an innovative and proven effective product against
diarrhea.” says Djamel Oulali, Senior Director Export in Ipsen Consumer
HealthCare.

SmectaGo® is a ready-to-drink suspension for use in the treatment of acute
diarrhea in adults and children above 8 years of age. The main component of the
product is diosmectite, a natural clay that helps in the inhibition and
treatment of diarrhea and in relieving abdominal pain.

Diarrhea is a common disease that affects adults and children from time to time,
and some patients suffer from chronic conditions. In Norway alone, intestinal
disorders accounts for up to 5000 consultations per week with general
practicioners. SmectaGO® is a product that can be bought in the pharmacies
without any prescription, and is different from any other product on the market
and uniquely characterized by its “stop and treat” mode of action:

· Ready to drink for a fast intake on the go
· Removes the toxins and germs
· Helps to repair intestinal damage
· Relieves abdominal pain

The agreement with Ipsen Consumer HealthCare will strengthen Navamedic’s
position in the gastroenterology category, which represents a significant growth
potential in the Consumer Health segment where patients can find approved
treatment options without prescriptions in the pharmacies. As part of the
agreement, Navamedic will also take over the distribution and sales in Sweden of
Forlax®, a prescription drug for the treatment of constipation in adults and
children aged 8 years and above.

“Navamedic has a target of 20 percent annual organic growth and the mid-term
ambition of building a NOK 500 million company, as we continue to accelerate
growth through launch of new products and push for growth in our existing
portfolio. The launch of SmectaGO® is a perfect example on how we like to
develop categories and drive growth,” says Kathrine Gamborg Andreassen, CEO of
Navamedic ASA.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visitwww.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · februar 17, 2022, 7:01am

Navamedic ASA: Resultater for fjerde kvartal 2021

Oslo, 17. februar 2022 - Navamedic ASA (OSE: NAVA) økte driftsinntektene med 63
% i fjerde kvartal 2021 sammenlignet med samme kvartal i 2020. Selskapet
rapporterte driftsinntekter på NOK 90,2 millioner i fjerde kvartal 2021, med en
…

Vis børsmeldingen

EBITDA på NOK 7,6 millioner, drevet av underliggende vekst i porteføljen og
spesielt for fedmelegemiddelet Mysimba®. Selskapet gjentar sin ambisjon om på
mellomlang sikt å bli et selskap med NOK 500 millioner i omsetning gjennom
organisk vekst.

Navamedic avsluttet 2021 sterkt. Inntektene for året 2021 økte med 33 %
sammenlignet med vårt mål om 20 % vekst. Vi hadde økt etterspørsel gjennom
kvartalet drevet av utvikling av kategorier og merkevarer spesielt innenfor
Consumer Health og Specialty Pharma. Med en inntektsvekst på 142% i fjerde
kvartal sammenlignet med samme kvartal i fjor er Speciality Pharma nå vår
største produktkategori. Dette var i stor grad et resultat av den imponerende
veksten for Mysimba. Dermed hjelper vi stadig flere fedmepasienter over hele
Norden i å lykkes med behandlingen. Vi er også glade for å se den gode
utviklingen for våre antibiotikaprodukter, sier Kathrine Gamborg Andreassen,
administrerende direktør i Navamedic, og fortsetter:

Veksten i fjerde kvartal har ytterligere styrket vår trygghet om å nå vårt mål
om 20 % årlig organisk vekst og ambisjonen om å bli et selskap med NOK 500
millioner i omsetning på mellomlang sikt. Vi fortsetter å vokse gjennom
lansering av nye produkter og ved å videreutvikle vår eksisterende portefølje
kommersielt. Navamedic har som mål å lansere produkter i minst ett land i hvert
lanseringsvindu fremover.

Nylig annonserte Navamedic lanseringen av Smecta® og Forlax®, produkter som
styrker selskapets portefølje innen gastro-segmentet.

Dette er et godt eksempel på hvordan vi driver vekst innenfor
produktkategorien Consumer Health. Gastro er et underutviklet segment i Norden,
til tross for at en stor andel av befolkningen har mage-tarm relaterte
problemer. Vi ser derfor et stort potensial ved å øke bevisstheten rundt mulige
behandlingsformer, sier Kathrine Gamborg Andreassen.

I fjerde kvartal 2021 var Navamedics driftsinntekter NOK 90,2 millioner (55,3
millioner i fjerde kvartal 2020). Bruttomarginen var 41,9 % (40,4%), og EBITDA
var NOK 7,6 millioner (negativ NOK 3,7 millioner). For 2021 totalt sett økte
driftsinntektene med 32,7 % sammenlignet med 2020, opp fra NOK 209,8 millioner
til NOK 278,4 millioner. EBITDA endte på NOK 18,2 millioner i 2021, opp fra
negativ NOK 1,3 millioner i 2020.

Navamedic avholder en presentasjon for fjerde kvartal 2021 torsdag 17. februar
kl. 08.45. Presentasjonen vil bli holdt hos Sparebank 1 Markets i Olav V’s gate
5 i Oslo og som webcast på www.navamedic.com/investors/financial-results, under
‘2021’. Presentasjonen vil holdes av administrerende direktør Kathrine Gamborg
Andreassen og finansdirektør Lars Hjarrand.

EBITDA og andre alternative resultatmål (APMer) er definert og avstemt med IFRS
-regnskapet som en del av APM-delen på side 24 i vedlagte presentasjon for
fjerde kvartal 2021.

For ytterligere informasjon, vennligst kontakt:

Kathrine Gamborg Andreassen, administrerende direktør, Navamedic

Mobil: +47 951 78 680

E-post: kathrine@navamedic.com

Lars Hjarrand, finansdirektør, Navamedic

Mobil: +47 917 62 842

E-post: lars.hjarrand@navamedic.com

Navamedic ASA er et nordisk farmaselskap som leverer høykvalitetsprodukter til
sykehus og apotek. Vår ambisjon er å ivareta pasienters og forbrukeres behov
gjennom dybdekompetanse innen utvalgte kategorier, samt inngående kunnskap om
lokale forhold i hvert marked. Navamedic er til stede i de nordiske landene,
Baltikum og Benelux, og har salgsrepresentasjon i Storbritannia og Hellas.
Navamedic har hovedkontor i Oslo og er notert på Oslo Børs (ticker: NAVA). For
mer informasjon, vennligst besøk www.navamedic.com.

Denne informasjonen er vurdert å inneholde innsideinformasjon i henhold til EUs
markedsmisbruksforordning (MAR) Artikkel 7, og er meldepliktig i henhold til
Verdipapirhandelloven §5-12.

Kilde

TekBot · februar 17, 2022, 7:01am

Navamedic ASA: Q4 2021 financial results

Oslo, 17 February 2022 - Navamedic ASA (OSE: NAVA) grew revenues by 63% in the
fourth quarter of 2021 compared to the same quarter last year. The company
reported revenues of NOK 90.2 million in the fourth quarter of 2021 with an
…

Vis børsmeldingen

EBITDA of NOK 7.6 million, driven by underlying growth in the portfolio and
Mysimba® in particular. The company reiterates its mid-term ambition of building
a NOK 500 million company through organic growth.

“The fourth quarter of 2021 was strong for Navamedic, resulting in a full year
growth of 33%, compared to our targeted growth rate of 20%. We have seen an
increased demand for our products driven by successful development of categories
and branded products particularly within Consumer Health and Specialty Pharma.
The latter is now our largest product area, following a growth of 142 percent in
revenue in the fourth quarter 2021 compared to the same period in 2020. This was
largely a result of the impressing development of Mysimba, helping obesity
patients across the Nordics to succeed in their treatment. We are also pleased
to see the strong performance of our portfolio of antibiotics products,” says
Kathrine Gamborg Andreassen, Chief Executive Officer of Navamedic ASA, and
continues:

“The strong growth in the fourth quarter has reinforced our confidence in the
communicated target of 20% annual organic growth and the mid-term ambition of
building a NOK 500 million company, as we continue to accelerate growth through
launch of new products and push for growth in our existing portfolio. We target
the launch of new products in at least one country in each launch window going
forward.”

Navamedic has recently announced the launch of SmectaGO® and Forlax®, adding to
a growing portfolio in the gastro segment.

“This is a good example of how we drive category growth within consumer health.
Gastro is an underdeveloped segment in the Nordics, even though a large portion
of the population has gastro related problems. Hence, we see a significant
potential in growing awareness of the potential treatments and strengthening our
brand positions,” says Kathrine Gamborg Andreassen.

Revenues in the fourth quarter of 2021 were NOK 90.2 million (NOK 55.3 million
in the fourth quarter of 2020). The gross margin was 41.9% (40.4%), while the
EBITDA was NOK 7.6 million (negative 3.7 million). For the full year 2021,
revenues grew by 32.7% compared to last year, up from NOK 209.8 million to NOK
278.4 million, while EBITDA was NOK 18.2 million, up from negative NOK 1.3
million last year.

Navamedic is hosting a presentation of the fourth quarter 2021 financial
results, Thursday 17 February 2022 at 08.45 CET. The presentation will be held
at Sparebank 1 Markets in Olav V’s gate 5 in Oslo as well as via webcast on
www.navamedic.com/investors/financial-results under ‘2021’. Representatives from
Navamedic will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached fourth quarter 2021 presentation on slide 24.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please visit
www.navamedic.com

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation article 7 and is subject to the disclosure requirements
pursuant to section 5-12 of the Norwegian Securities Trading Act.

Kilde

Quadruple · februar 17, 2022, 8:46am

Navamedic delivered its 4Q21 report with promising figures. Revenues came in at NOK 90.2m vs NOK 84.3m expected by us. This indicates a YoY revenue growth for 2021 at 33%, even higher than the increased guidance of 30% in the December update. Gross margin was at 42% and already higher than that mid-term guidance of 40%. EBITDA has came in at NOK 7.6m vs NOK 6.7m expected by us. With a 4Q EBITDA margin of 8.4%, Navamedic is well on their way to reach the mid-term goal of 15% EBITDA margin. Lower than expected EPS were mainly caused by higher depreciation and negative exchange rate differences. (Nornes kommentar idag)

Quadruple · februar 17, 2022, 9:32am

Quadruple · februar 18, 2022, 9:12am

Høyner kursmålet:

" Even stronger growth with improving profitability

Navamedic has announced its 4Q results with exceptionally high YoY revenues, powered by Specialty pharma and MySimba ® growth. With a strong momentum moving forward, we raise our revenue growth expectations for 2022 and increase our TP to NOK 53/sh (50)." (Norne)

TekBot · april 29, 2022, 6:02am

Navamedic: Annual report 2021

Oslo, 29 April 2022 - Navamedic ASA (OSE: NAVA) publishes its annual report for
2021. The report is attached and available on navamedic.com/investors.
Additionally, the company’s Annual Report in European Single Electronic Format
…

Vis børsmeldingen

(ESEF) is attached, please refer to the zip-file.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail:
kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail:
lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mai 5, 2022, 8:22am

Navamedic ASA acquires Impolin AB and broadens obesity portfolio

Oslo, 5 May 2022 – Navamedic ASA (“NAVA” or the “Company”) (OSE: NAVA) today announces that it has entered into a share purchase agreement with Agnvicen AB to acquire 100% of the shares in Impolin AB for a purchase price of SEK 50 million on a debt and cash free basis. In addition, the seller may be entitled to an additional consideration in the amount of SEK 5 million if certain pre-agreed milestones for Impolin AB are satisfied by year-end 2022.

Navamedic will settle SEK 25 million of the purchase price by way of issuing new shares to the seller through conversion of an account receivable to be issued by Navamedic to the seller at closing. The remaining portion of the purchase price will be settled in cash. The subscription price for the new shares shall be equal to the volume weighted average share price of the Company’s shares on the Oslo Stock Exchange during the period from 31 December 2021 to the closing date of the transaction. The consideration shares will be listed on the Oslo Stock Exchange and be subject to a lock-up period of 24 months from the closing date. The board of directors of Navamedic will issue the consideration shares pursuant to an authorization to issue new shares granted to it by the general meeting of the Company on 3 June 2021 or, if completion occurs after the expiry of such authorization, a new authorization to be approved by the Annual General Meeting of the Company.
…

Vis børsmeldingen

The completion of the transaction is subject to Impolin AB amending one of its material agreements on terms and conditions satisfactory to Navamedic, in addition to certain customary conditions. It is expected that the transaction will be completed during Q2 2022.

Upon closing of the transaction, Impolin AB will become a 100% wholly owned subsidiary of Navamedic ASA. Impolin AB is a Stockholm based company that specializes in products related to the pre- and post-treatment for bariatric surgery and has built a strong position in Sweden for the products Modifast and MedMade.

This information is considered to be inside information pursuant to the EU Market Abuse Regulation article 7 and is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Lars Hjarrand, CFO of Navamedic, on 5 May 2022 at 10:20 CEST on behalf of the Company.

–

For further information, please contact:
Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to hospitals and pharmacies. Navamedic meets the specific medical needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

Kilde

Quadruple · mai 5, 2022, 9:02am

https://www.largestcompanies.no/bedrift/Impolin-AB-472179/regnskap-og-nokkeltall

TekBot · mai 5, 2022, 9:36am

Navamedic ASA acquires Impolin AB and bolsters its product portfolio

· The proposed acquisition reinforces Navamedic’s position in the market for
obesity treatment
· The acquired portfolio enables Navamedic to support patients and consumers
…

Vis børsmeldingen

during weight loss or obesity treatment
· This agreement supports Navamedic’s ambition to become a leading Nordic
provider of specialized, high-quality products to hospitals and pharmacies

Oslo, 5 May 2022 - Navamedic ASA (OSE: NAVA), a Nordic pharma company and
reliable provider of high-quality products to hospitals and pharmacies, and
Impolin AB (Impolin), a Swedish-based, independent distributor of products that
benefit the health and wellbeing of consumers and patients, today announce that
Navamedic will acquire Impolin to expand its product portfolio for obesity
treatment.

Impolin’s portfolio includes Modifast, a range of diet and meal replacement
products, and MedMade, a multivitamin and minerals tablet for post-bariatric
surgery supplementation, which are products aimed at supporting patients during
weight loss or obesity treatment, including bariatric surgery. Impolin’s third
product is Absolut Torr/Absolute Dry, extra effective antiperspirants primarily
for hyperhidrosis, excessive sweating.

The addition of Modifast and MedMade is set to broaden Navamedic’s current
product offering within the area of obesity treatment and enables Navamedic to
support patients throughout the entire weight loss journey.

Obesity is considered a disease that increases the likelihood of various other
diseases and conditions, such as type 2 diabetes and cardiovascular disease.
Between 15-and 20%[1] of people in the Nordic population are considered obese,
whereby the cost of treatment and related complications are increasing. Weight
loss remains the key in the management of obesity and is often a prerequisite
for patients seeking to undergo bariatric surgery.

"The world has seen obesity nearly triple since 1975, making it a significant
public health concern. Navamedic has been ramping up activities in this
important segment and is now in an ideal position to improve the product
offering for patients and consumers seeking to undergo weight loss in a safe and
effective way.

“Our ambitions are bold, but by capitalizing on the strong transaction
synergies, I am confident that we will successfully launch our expanded product
range across the Nordic territory. Together with the Impolin team, we are
planning to launch Modifast in Norway in 2023, followed by rollout in Finland
and Denmark, and double product revenue by the end of 2028,” commented Kathrine
Gamborg Andreassen, CEO of Navamedic.

“Navamedic has dedicated part of its product portfolio to treating obesity,
making the company our preferred partner. With Navamedic’s position as a
reliable supplier of high-quality products in the Nordics, we believe this
agreement will accelerate access to our products for patients outside of Sweden.
I look forward to collaborating closely with the team at Navamedic to contribute
to improving the quality of life for people,” said Tony Brejke, Managing
Director and owner of Impolin AB.

For further information, please contact: Kathrine Gamborg Andreassen, CEO,
Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com Lars Hjarrand,
CFO, Navamedic Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

About Impolin AB

Impolin AB (Impolin) is a Swedish-based, independent distributor of products
that benefit the health and wellbeing of consumers and patients. The portfolio
includes own brands as well as international distribution agreements. Pharmacies
are the sole distribution channel, alongside the branded website with e-trade.
The company also exports Absolut Torr, to other countries and regions, via third
party distributors. For more information, please visit www.impolin.com

[1] World Obesity. Global Obesity Observatory https://data.worldobesity.org/.

Kilde

Quadruple · mai 5, 2022, 11:39am

Og på norsk:

TekBot · mai 9, 2022, 6:51am

Navamedic ASA: Invitation to 2022 first quarter presentation

Oslo, May 9, 2022 - Navamedic ASA (OSE: Nava) will be presenting its first quarter 2022 results on Tuesday, May 10th.

The presentation will be held at Haakon VIIs gate 2 in Oslo and the event will start at 08.30 CET. The live webcast will be available at the following link:
…

Vis børsmeldingen

https://channel.royalcast.com/landingpage/hegnarmedia/20220510_5/

For further information, please contact:
Kathrine Gamborg Andreassen, CEO, +47 951 78 680 E-mail: kathrine@navamedic.com
Lars Hjarrand,CFO, +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

About Navamedic

Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com

Kilde

TekBot · mai 10, 2022, 6:02am

Navamedic ASA: Resultater for første kvartal 2022

Oslo, 10. mai 2022 - Navamedic ASA (OSE: NAVA) økte driftsinntektene med 7,4
prosent i første kvartal 2022 sammenlignet med samme periode i 2021.

…

Vis børsmeldingen

Første kvartal var solid, og vi leverte fortsatt vekst som følge av nye
produktlanseringer og sterk utvikling for produktkategoriene Medical Nutrition,
Consumer Health og Branded Generics. Vår type virksomhet vil alltid oppleve
visse svingninger i veksttakt fra kvartal til kvartal på grunn av oppbygging
eller nedtrekk av lagerbeholdninger, og i første kvartal opplevde vi en
midlertidig stopp i forsyningen av vårt fedmeprodukt Mysimba.
Leveringsproblemene er nå løst, og vi får levert Mysimba igjen nå i mai. Det
betyr at vi fortsatt er i rute når det gjelder å nå vårt mål om 20 prosent årlig
organisk inntektsvekst for 2022 og fremover, sier Kathrine Gamborg Andreassen,
administrerende direktør i Navamedic.

Navamedics rullerende 12 måneders omsetning var i første kvartal NOK 283
millioner, en vekst på 33 prosent sammenlignet med samme tidspunkt i 2021, og
selskapet har levert positiv rullerende 12 måneders EBITDA i fem kvartaler på
rad.

Vekstmodellen vår har vist seg å fungere godt over tid, og vi fortsetter å
innfri vår ambisjon om å utnytte potensialet i vår eksisterende portefølje,
inngå nye distribusjonsavtaler, utvikle nye merkevarer og kjøpe opp produkter og
porteføljer. I dag oppdaterer vi vår uttalte vekstambisjon. Ambisjonen er å nå
en omsetning på 1 milliard kroner på mellomlang sikt, sier Kathrine Gamborg
Andreassen.

Navamedics bruttomargin var på 39,4 prosent i første kvartal, uendret
sammenlignet med samme periode i 2021. EBITDA var NOK -0,4 millioner
sammenlignet med NOK 2,6 millioner i første kvartal i fjor. Nedgangen i EBITDA
var et resultat av økte markedsføringskostnader knyttet til lanseringer av nye
produkter.

I første kvartal gjennomførte vi en vellykket lansering av SmectaGO®, et
innovativt produkt for behandling av diaré, og vi har som mål å lansere minst
ett nytt produkt i ett av landene våre i hvert lanseringsvindu, sier Kathrine
Gamborg Andreassen.

Navamedic fortsetter også å gjøre oppkjøp. I mai 2022 ble kjøpet av Impolin AB
offentliggjort, og dette styrker Navamedics posisjon i markedet for
fedmebehandling. Impolins portefølje består av produkter med en sterk posisjon i
Sverige, og Navamedics ambisjon er å lansere Modifast, en rekke diett- og
måltidserstatningsprodukter, i Norge i 2023, etterfulgt av utrulling i Finland
og Danmark.

Navamedic avholder en presentasjon av resultatet før første kvartal 2022 tirsdag
10. mai kl. 08.30. Presentasjonen vil bli holdt hos Haakon VII Gate 2 i Oslo og
som webcast på www.navamedic.com/investors/financial-results, under 2022.
Presentasjonen vil holdes av administrerende direktør Kathrine Gamborg
Andreassen og finansdirektør Lars Hjarrand.

EBITDA og andre alternative resultatmål (APMer) er definert og avstemt med IFRS
-regnskapet som en del av APM-delen på side 26 i vedlagte presentasjon for
fjerde kvartal 2021.

For ytterligere informasjon, vennligst kontakt:

Kathrine Gamborg Andreassen, administrerende direktør, Navamedic

Mobil: +47 951 78 680

E-post: kathrine@navamedic.com

Lars Hjarrand, finansdirektør, Navamedic

Mobil: +47 917 62 842

E-post: lars.hjarrand@navamedic.com

Navamedic ASA er en fullspekter leverandør av høykvalitetsprodukter til sykehus
og apotek. Navamedig ivareta pasienters og forbrukeres behov ved å utnytte sin
skalerbare plattform for markedstilgang, gjennom dybdekompetanse innen utvalgte
kategorier, samt inngående kunnskap om lokale forhold i hvert marked. Navamedic
er til stede i de nordiske landene, Baltikum og Benelux, og har
salgsrepresentasjon i Storbritannia og Hellas. Navamedic har hovedkontor i Oslo
og er notert på Oslo Børs (ticker: NAVA). For mer informasjon, vennligst besøk
www.navamedic.com.

Denne informasjonen er vurdert å inneholde innsideinformasjon i henhold til EUs

markedsmisbruksforordning (MAR) Artikkel 7, og er meldepliktig i henhold til

Verdipapirhandelloven §5-12. Meldingen ble publisert av Lars Hjarrand på
tidspunktet angitt ovenfor.

Kilde

TekBot · mai 12, 2022, 11:21am

Navamedic ASA: Notice of Annual General Meeting

TekBot · mai 31, 2022, 12:30pm

NAVAMEDIC ASA: RESOLUTION TO INCREASE THE SHARE CAPITAL IN CONNECTION WITH EXERCISE OF EMPLOYEE OPTIONS

Oslo, 31 May 2022: The board of directors of Navamedic ASA (the “Company”), has today, on 31 May 2022, in accordance with the authorisation granted to it by the general meeting on 3 June 2021, resolved to increase the Company’s share capital by NOK 55,500 by issuance of 75,000 new shares, each with a nominal value of NOK 0.74, in order to facilitate the settlement of exercise of 75,000 share options. The exercise prices are NOK 14.46 per share for 50,000 of the new shares and NOK 19.00 per share for 25,000 of the new shares. The shares are subject to a 12 month lock-up period.

Following the registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret), the new share capital of the Company will be NOK 12,151,288.40, divided into 16,420,660 shares, each with a nominal value of NOK 0.74. The share capital increase will be registered with the Norwegian Register of Business Enterprises as soon as practically possible after the share contribution has been fully paid.
…

Vis børsmeldingen

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA:
Navamedic ASA is a Nordic full-service provider of high-quality products to hospitals and through pharmacies. Navamedic meets the specific needs of patients and consumers by leveraging its highly scalable market access platform, leading category competence and local knowledge. Navamedic is present in all the Nordic countries, the Baltics and Benelux, with sales representation in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock Exchange (ticker: NAVA).
For more information, please visit www.navamedic.com.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mai 31, 2022, 1:55pm

Navamedic ASA – Mandatory notification of trade by primary insider

Oslo, 31 May 2022: Reference is made to the stock exchange announcement published earlier today, on 31 May 2022 by Navamedic ASA (the “Company” or “Navamedic”), regarding the board of directors’ resolution to increase the Company’s share capital with NOK 55,500 by the issuance of 75,000 new shares, in order to facilitate the settlement of exercise of 75,000 share options in the Company.

Primary insider, Lars Hjarrand, CFO of Navamedic, has today, on 31 May 2022, exercised 75,000 share options in the Company under his option agreements from 2019 and 2020, respectively, and subscribed for 75,000 new shares in the Company following such option exercise. Following the option exercise and subscription of the new shares, Lars Hjarrand holds 260,882 shares and 75,000 options in the Company.
…

Vis børsmeldingen

Please refer to the attached notification of trading for further details.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · juni 1, 2022, 2:08pm

Navamedic ASA completes acquisition of Impolin AB and issues consideration shares

Oslo, 1 June 2022 - Navamedic ASA (“Navamedic” or the “Company”) (OSE: NAVA)
today announces that it has completed the acquisition of Impolin AB, as
announced by the Company on 5 May 2022.
…

Vis børsmeldingen

As partial settlement of the purchase price for the acquisition, the board of
directors of Navamedic has today, on 1 June 2022, resolved to increase the
Company’s share capital with NOK 597,266.58 by issuance of 807,117 new shares in
the Company to Agnvicen AB, being the seller of Impolin AB, each with a nominal
value of NOK 0.74. The consideration shares were issued at a subscription price
of NOK 29.7757 per consideration share upon conversion of an account receivable
of NOK 24,032,500. The subscription price for the consideration shares is equal
to the volume weighted average share price of the Company’s shares on the Oslo
Stock Exchange during the period from (but not including) 31 December 2021 to
(but not including) the closing date of the acquisition. The share capital
increase was resolved by the board of directors under the authorisation to
increase the Company’s share capital granted by the annual general meeting held
on 3 June 2021. To complete Navamedic’s obligations pursuant to the share
purchase agreement for the acquisition of Impolin AB, the preferential right of
the existing shareholders was deviated from. The consideration shares are
subject to a lock-up period of 24 months on the terms and conditions of the
share purchase agreement.

Following the registration of the share capital increase pertaining to the
consideration shares with the Norwegian Register of Business Enterprises (Nw.
Foretaksregisteret), the share capital of Navamedic will be NOK 12,748,554.98,
divided into 17,227,777 shares, each with a nominal value of NOK 0.74.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic
Mobile: +47 951 78 680
E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic
Mobile: +47 917 62 842
E-mail: lars.hjarrand@navamedic.com

About Navamedic ASA:

Navamedic ASA is a Nordic full-service provider of high-quality products to
hospitals and through pharmacies. Navamedic meets the specific needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in the UK and
Greece. Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA).

For more information, please visit www.navamedic.com.

This information is subject of the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde